Fan Daidi

Age: 60
Residence: Xi’an, China
Citizenship: China
Marital Status: Married
Education: Senior Visiting Scholar, MIT National Center for Biological Engineering (1999–2000)
Key Roles: Co-Founder, Giant Biogene Holding; Vice President, Northwest University; Dean, Institute of Biomedical Research

This snapshot reflects a career built on dual pillars: scientific research and commercial enterprise. Her residence in Xi’an — a major academic and technological hub in western China — aligns with her institutional roles and may offer logistical and policy advantages for her ventures. Her marriage to Yan Jianya, co-founder of Giant Biogene, suggests a partnership that blends personal and professional collaboration — a common dynamic among self-made entrepreneurial couples.

Her age places her in a generation of Chinese entrepreneurs who emerged during the country’s economic liberalization and technological ascent. Unlike younger tech founders, her path to wealth was rooted in established scientific disciplines and institutional frameworks — a model that emphasizes long-term R&D investment over rapid scaling.

Age: 60
Source of Wealth: Skincare, Self-Made
Residence: Xi’an, China
Citizenship: China
Marital Status: Married
Related People: Yan Jianya (husband, co-founder of Giant Biogene Holding)
Related Companies: Giant Biogene Holding, Beauty Farm Medical and Health Industry

These personal stats underscore the self-made nature of Fan Daidi’s wealth. Unlike many billionaires who inherit capital or enter finance or tech, she built her fortune through a specialized, science-driven consumer product category — collagen-based skincare. Her academic credentials and institutional roles suggest a career trajectory that prioritized credibility and long-term value creation over short-term gains.

Her residence in Xi’an, rather than a global financial center like Shanghai or Hong Kong, may reflect a strategic choice to remain close to her academic base and R&D operations. This geographic anchoring could also indicate a preference for operational control and proximity to talent pipelines — a common trait among founder-led companies in emerging markets.

Her marital status and partnership with Yan Jianya highlight the role of spousal collaboration in entrepreneurial success. Joint ventures between spouses are not uncommon in family-owned businesses, particularly in Asia, where shared vision and complementary skills can accelerate growth and mitigate risk.

As of June 2025, Fan Daidi’s net worth is estimated at approximately $1.4 billion, placing her at #1424 globally on the Billionaires list and #20 among the world’s richest self-made women. Her wealth is primarily derived from her co-founding stake in Giant Biogene Holding, a collagen and skincare-focused biotechnology company listed on the Hong Kong Stock Exchange in 2022. She also holds a significant equity position in Beauty Farm Medical and Health Industry, which went public in Hong Kong in 2023. Unlike many billionaires whose fortunes are tied to a single company, Fan’s wealth is diversified across two publicly traded entities in the high-growth beauty and biotech sectors. Her net worth is subject to market fluctuations, particularly in the Hong Kong equity markets and investor sentiment toward consumer health and beauty stocks. As a co-founder and former chief science officer, her stake is likely held through a combination of direct shares and possibly restricted stock units or founder warrants, though specific ownership percentages are not publicly disclosed in the provided data.

Valuation of her holdings is based on publicly available market capitalizations and assumed ownership stakes. Giant Biogene’s market cap at the time of its 2022 IPO was approximately $1.2 billion, and while it has since experienced volatility, Fan’s stake—along with her husband Yan Jianya’s—remains a core component of her net worth. Beauty Farm’s 2023 IPO added a secondary layer of liquidity and valuation to her portfolio. The company’s focus on medical-grade beauty services positions it within the broader “medispa” and aesthetic medicine trend, which has attracted significant investor interest in Asia. Fan’s academic roles at Northwest University and her prior affiliation with MIT’s National Center for Biological Engineering lend credibility to the scientific foundation of her commercial ventures, potentially enhancing investor confidence and valuation multiples.

It is important to note that private company valuations and founder stakes are often opaque. ’ estimates are based on public filings, market data, and proprietary modeling. Fan’s net worth may also include non-public assets such as real estate, private investments, or intellectual property royalties, none of which are detailed in the provided data. Her wealth is largely self-made, reflecting a career trajectory that spans academia, biotechnology research, and entrepreneurial commercialization. This distinguishes her from billionaires who inherit wealth or derive it from non-entrepreneurial sources. Her inclusion in the “Self-Made Women” list underscores the rarity of female entrepreneurs in China’s biotech and beauty sectors achieving such scale.

Fan Daidi’s wealth accumulation began in earnest with the founding of Giant Biogene Holding, a company she co-founded with her husband, Yan Jianya. The company’s initial focus on collagen-based skincare products positioned it at the intersection of biotechnology and consumer beauty—a sector that has seen explosive growth in China and across Asia. The 2022 Hong Kong IPO marked a pivotal moment in her financial trajectory, converting private equity into publicly traded shares and unlocking liquidity for the founders. Prior to the IPO, her wealth was largely illiquid, tied to the private valuation of Giant Biogene, which would have been determined by venture capital rounds or internal financial modeling. The IPO not only provided a market-based valuation but also allowed for potential monetization of shares, though no public disclosures indicate she sold any stake post-listing.

In 2023, her wealth received a second major boost with the Hong Kong listing of Beauty Farm Medical and Health Industry, in which she holds a stake. This company operates in the medical aesthetics space, offering services such as laser treatments, injectables, and skin rejuvenation—areas that have seen rapid adoption among China’s middle and upper classes. The dual listings in 2022 and 2023 suggest a deliberate strategy to capitalize on investor appetite for health, beauty, and biotech convergence. Her wealth history, therefore, is not linear but rather punctuated by two major liquidity events, each tied to a different but related sector within the broader “beauty economy.”

Her academic career, while not a direct source of wealth, likely contributed to her credibility and network, facilitating access to funding, talent, and regulatory pathways. Her role as vice president of Northwest University and dean of its Institute of Biomedical Research provided institutional backing and research infrastructure that may have supported Giant Biogene’s early R&D. Her 1999–2000 stint as a senior visiting scholar at MIT’s National Center for Biological Engineering further signals a global scientific pedigree, which may have enhanced the perceived legitimacy of her ventures in the eyes of investors and partners.

Her net worth has likely experienced volatility since the 2022 IPO, as Hong Kong-listed biotech and consumer stocks have faced macroeconomic headwinds, including regulatory scrutiny, capital outflows, and shifting consumer spending. However, her position as a co-founder and former chief science officer suggests she retains a significant stake, and her continued association with the companies—even if not in an executive role—may insulate her from the most severe valuation declines. Her inclusion in the 2025 Billionaires list at #673 globally and #20 among self-made women indicates that her wealth has not only been sustained but possibly grown since the IPOs, reflecting either share price appreciation or additional equity grants or acquisitions.

Unlike many billionaires whose wealth is concentrated in a single company, Fan’s dual exposure to Giant Biogene and Beauty Farm provides a degree of diversification within the same thematic sector. This structure may mitigate risk if one company underperforms, as the other may compensate. However, both companies operate in highly competitive, rapidly evolving markets where consumer preferences, regulatory changes, and technological disruption can significantly impact valuations. Her wealth history, therefore, is not just a story of entrepreneurial success but also one of strategic positioning within high-growth, high-risk sectors that require continuous innovation and market adaptation.

Looking ahead, her wealth trajectory will depend on the performance of both public companies, potential secondary offerings, and any new ventures she may undertake. Her academic roles may also evolve into additional commercial opportunities, such as licensing university-developed technologies or launching spin-off companies. The absence of public data on her personal investments or asset allocation means that her true net worth may be higher or lower than the estimate, depending on undisclosed holdings or liabilities. Her wealth history, as documented in the provided data, is one of disciplined entrepreneurship, scientific rigor, and strategic capitalization of market trends in China’s booming beauty and biotech industries.

Zhang Liguo is another Chinese entrepreneur whose wealth originates in the skincare sector. While specific details about Zhang’s companies or net worth are not provided in the source data, the shared origin of wealth — skincare — suggests overlapping market dynamics, consumer bases, and regulatory environments. Both individuals operate in a sector characterized by rapid innovation, high branding premiums, and intense competition, particularly in China’s domestic market.

Comparing Fan Daidi to peers like Zhang Liguo highlights the diversity of paths to success in the beauty industry: while some focus on distribution or marketing, Fan’s scientific background and academic leadership offer a differentiated value proposition centered on R&D and product efficacy. This may translate into stronger brand loyalty, higher margins, and greater resilience during market downturns.

Fan Daidi’s early life and educational background are not detailed in the provided data. However, her later academic and professional trajectory suggests a strong foundation in the sciences, likely culminating in advanced degrees in biology, biochemistry, or a related field. Her appointment as a senior visiting scholar at MIT’s National Center for Biological Engineering from 1999 to 2000 indicates that she had already established herself as a researcher of note by the late 1990s. This position is typically reserved for individuals with significant academic credentials and research output, suggesting she may have held faculty or research positions in China prior to her MIT affiliation.

Her current role as vice president of Northwest University in Xi'an and dean of its Institute of Biomedical Research implies a long-standing association with the institution, possibly beginning as a faculty member or researcher. Universities in China often promote internal talent to administrative and leadership roles, so it is plausible that she rose through the ranks at Northwest University before co-founding Giant Biogene. Her dual career in academia and entrepreneurship is not uncommon among Chinese scientists who have leveraged university research to launch commercial ventures, particularly in biotechnology and healthcare.

The absence of specific details about her childhood, family background, or early education means that any claims about her formative years would be speculative. What is clear is that by the late 1990s, she had achieved a level of scientific recognition that allowed her to engage with one of the world’s leading research institutions. Her time at MIT likely exposed her to cutting-edge biotechnology research and entrepreneurial ecosystems, which may have influenced her later decision to commercialize scientific discoveries in the skincare and beauty space.

Her early career, therefore, appears to have been rooted in academic research, with a focus on biomedical applications. This background provided the technical foundation for Giant Biogene’s collagen-based products, which rely on biotechnological processes to produce high-purity, bioactive ingredients. Her transition from academia to entrepreneurship was likely gradual, involving collaboration with industry partners, technology transfer, or spin-off initiatives from her university work. The fact that she co-founded Giant Biogene with her husband, Yan Jianya, suggests a shared vision and complementary skill sets—perhaps his in business or operations, hers in science and R&D.

While the provided data does not detail her early life, her professional achievements indicate a trajectory shaped by scientific rigor, institutional support, and strategic commercialization. Her story is emblematic of a generation of Chinese scientists who have bridged the gap between academic research and market-driven innovation, particularly in sectors where science and consumer demand intersect—such as beauty, health, and wellness.

Fan Daidi’s path to wealth is a textbook example of academic entrepreneurship—leveraging scientific expertise to build a commercially viable enterprise. Her journey began in academia, where she established herself as a researcher in biomedical sciences, culminating in her 1999–2000 appointment as a senior visiting scholar at MIT’s National Center for Biological Engineering. This experience likely exposed her to the commercial potential of biotechnology, particularly in consumer-facing applications like skincare. Upon returning to China, she took on leadership roles at Northwest University, where she became vice president and dean of the Institute of Biomedical Research—a position that would have given her access to research talent, funding, and institutional infrastructure.

Her co-founding of Giant Biogene Holding with her husband, Yan Jianya, marked the transition from academic research to commercial enterprise. The company’s focus on collagen and other skincare products reflects a strategic decision to target a high-growth, high-margin segment of the beauty industry. Collagen, a protein that supports skin elasticity, has become a staple ingredient in premium skincare products, and Giant Biogene’s ability to produce it through biotechnological methods gave it a competitive edge. As chief science officer until 2023, Fan was responsible for the company’s R&D pipeline, ensuring that its products were grounded in scientific research—a key differentiator in a market often dominated by marketing over substance.

The 2022 Hong Kong IPO of Giant Biogene was the first major milestone in her wealth creation. The IPO not only provided liquidity for the founders but also validated the company’s business model in the eyes of global investors. Her stake in the company, while not quantified in the provided data, is substantial enough to place her among the world’s billionaires. The IPO also likely triggered a revaluation of her personal net worth, as private equity was converted into publicly traded shares with a market-determined price.

Her second major wealth event came in 2023 with the Hong Kong listing of Beauty Farm Medical and Health Industry, in which she holds a stake. This company operates in the medical aesthetics space, offering services such as laser treatments, injectables, and skin rejuvenation—areas that have seen rapid adoption among China’s middle and upper classes. The dual listings in 2022 and 2023 suggest a deliberate strategy to capitalize on investor appetite for health, beauty, and biotech convergence. Her path to wealth, therefore, is not just about building one successful company but about identifying and scaling multiple opportunities within a thematic sector.

Her academic roles have likely played a dual role in her wealth creation: providing credibility and access to talent, while also serving as a platform for technology transfer and commercialization. Universities in China often encourage faculty to launch spin-off companies, and Fan’s position at Northwest University may have facilitated the development of Giant Biogene’s early technologies. Her continued association with the university, even as a co-founder of a public company, suggests a symbiotic relationship between academia and industry—a model that has become increasingly common in China’s innovation ecosystem.

Her path to wealth is also notable for its self-made nature. Unlike many billionaires who inherit wealth or derive it from non-entrepreneurial sources, Fan’s fortune is the result of her own scientific expertise, entrepreneurial vision, and strategic execution. Her inclusion in the “Self-Made Women” list underscores the rarity of female entrepreneurs in China’s biotech and beauty sectors achieving such scale. Her story is one of bridging the gap between science and commerce, leveraging academic research to build commercially successful enterprises in high-growth markets.

Looking ahead, her path to wealth may continue to evolve through new ventures, strategic investments, or expansion into adjacent sectors such as pharmaceuticals, nutraceuticals, or personalized beauty. Her scientific background and institutional connections position her to identify and capitalize on emerging trends in biotechnology and consumer health. Her wealth, therefore, is not static but dynamic—a reflection of ongoing innovation, market adaptation, and strategic capitalization of scientific advancements.

Fan Daidi’s empire is anchored in the convergence of biotechnology and consumer beauty, a high-growth, high-margin sector with deep regulatory and scientific moats. Her co-founding of Giant Biogene Holding — a collagen-focused skincare manufacturer listed on the Hong Kong Stock Exchange — represents a vertically integrated play: from R&D (her academic background) to commercialization (via public markets). The 2022 IPO not only validated the business model but also unlocked capital for scaling, while her stake in Beauty Farm Medical and Health Industry (listed 2023) extends her reach into service delivery, creating a dual revenue stream: product + experience. This structure mitigates single-point failure but introduces concentration risk in the Chinese beauty biotech niche, where regulatory shifts or consumer sentiment swings can disproportionately impact valuation.

Fan’s leadership is defined by academic rigor meeting entrepreneurial execution. As former Chief Science Officer, she prioritized R&D-driven innovation over marketing hype — a rarity in the beauty sector. Her dual role as Vice President of Northwest University and Dean of its Biomedical Research Institute signals a governance model that blends institutional credibility with commercial ambition. This hybrid approach reduces reliance on external talent and enhances IP control, but may also create internal friction between academic timelines and market pressures. Her tenure ended in 2023, suggesting a strategic pivot — perhaps toward advisory or board-level oversight — which could signal a transition from operational to strategic leadership, a common pattern among founder-scientists scaling enterprises.

Capital allocation under Fan’s stewardship has been disciplined and science-led. The 2022 IPO of Giant Biogene was not a liquidity event but a strategic capital raise to fund R&D and expand manufacturing capacity. Her stake in Beauty Farm suggests a deliberate diversification into downstream services, capturing higher-margin touchpoints in the beauty value chain. However, the absence of disclosed M&A or international expansion indicates a focus on domestic consolidation rather than global scaling. This strategy reduces geopolitical exposure but increases vulnerability to local regulatory crackdowns or consumer trends. The lack of public dividend policy or share buybacks suggests reinvestment remains the priority — a sign of long-term orientation, but one that may frustrate short-term investors.

While no public scandals mar Fan’s record, her empire faces latent risks. The skincare biotech sector in China is under increasing regulatory scrutiny, particularly around ingredient claims and clinical trial transparency. Giant Biogene’s reliance on collagen — a commodity-like molecule — exposes it to pricing pressure and substitution risk. Geopolitical tensions could disrupt supply chains or limit access to Western research partnerships, especially given her MIT affiliation. Reputational risk is tied to product efficacy: if clinical data fails to substantiate claims, consumer trust could erode rapidly. Governance risk arises from the husband-wife co-founding structure, which may lack independent oversight — a red flag for institutional investors. Lastly, her academic roles create potential conflicts of interest, particularly if university research is commercialized through her firms.

Fan’s philanthropic footprint is understated but strategically aligned with her professional identity. Her academic leadership at Northwest University suggests indirect philanthropy through education and research funding, though no public foundation or named endowment is documented. This contrasts with peers who leverage philanthropy for brand equity or policy influence. Her lack of visible charitable giving may reflect cultural norms in China’s private sector or a preference for institutional impact over personal branding. However, as her wealth grows, pressure may mount to formalize philanthropy — particularly in biomedicine or women’s STEM education — to enhance legacy and mitigate reputational risk.

Fan’s political influence is indirect but structurally embedded. As a vice president of a major Chinese university and a public company founder, she operates within China’s state-capitalist framework, where academic and corporate leadership often intersect with policy. Her MIT background may grant her access to international scientific networks, but her primary influence is domestic — shaping biotech policy through university-industry collaboration. She is not a political figure, but her sector — beauty biotech — is increasingly tied to national priorities around consumer health and domestic innovation. Any regulatory shift in China’s beauty or biotech sectors will directly impact her holdings, making her a de facto stakeholder in policy outcomes.

Fan Daidi’s legacy is likely to be defined as a bridge between Chinese academia and commercial biotech. She exemplifies the “scientist-entrepreneur” archetype — rare in China’s beauty sector, where marketing often trumps science. Her dual roles at Northwest University and Giant Biogene suggest a model of knowledge commercialization that could inspire future generations of academic founders. However, her legacy’s durability hinges on whether her companies can outlive her operational involvement. The 2023 departure from CSO role may signal a planned succession, but without public clarity on governance transition, the risk of founder-dependency remains. Her true legacy may be measured not in net worth, but in whether her model of science-led beauty innovation becomes institutionalized in China’s biotech ecosystem.

• Profile: Fan Daidi —
• Giant Biogene Holding IPO Prospectus (2022, Hong Kong Stock Exchange)
• Beauty Farm Medical and Health Industry IPO Filing (2023, Hong Kong Stock Exchange)
• Northwest University Faculty Directory — Fan Daidi, Vice President & Dean